Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Panacea Biotech Gains 12%; BSE HEALTHCARE Index Up 0.6%
Mon, 19 Aug 12:23

Panacea Biotech Gains 12%; BSE HEALTHCARE Index Up 0.6%Image source: Kameleon007 /www.istockphoto.com

Panacea Biotech share price has zoomed 12% and is presently trading at Rs 183.5.

Meanwhile, the BSE HEALTHCARE index is at 41,421.4 (up 0.6%).

Among the top gainers in the BSE HEALTHCARE index today are CAPLIN POINT (up 12.8%) and POLY MEDICURE (up 6.0%).

SUVEN PHARMACEUTICALS (down 2.6%) and FORTIS HEALTHCARE (down 2.1%) are among the top losers today.

Over the last one year, Panacea Biotech has moved up from Rs 130.8 to Rs 183.5, registering a gain of Rs 52.7 (up 40.3%).

On the other hand, the BSE HEALTHCARE index has moved up from 27,819.2 to 41,421.4, registering a gain of 48.9% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were GRANULES INDIA (up 127.6%), Jubilant Pharmova (up 109.2%) and GSK Pharma (up 107.3%).

Must See: These Segments are Witnessing Incredible Growth with Modi's Push

What About the Benchmark Indices?

The BSE Sensex is at 80,468.3 .

The top gainers among the BSE Sensex today are Tata Steel (up 1.5%) and NTPC (up 1.1%). The most traded stocks in the BSE Sensex are Tata Steel and NTPC.

In the meantime, NSE Nifty is at 24,575.3 (up 0.1%). Hindalco and BPCL are among the top gainers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 65,401.9 to 80,468.3, registering a gain of 15,066.4 points (up 23.0%).

Panacea Biotech Financial Update...

Panacea Biotech net profit fell 244.6% YoY to Rs -159 million for the quarter ended June 2024, compared to a profit of Rs 110 million a year ago. Net sales declined 10.4% to Rs 1,157 million during the period as against Rs 1,292 million in April-June 2023.

For the year ended March 2023, Panacea Biotech reported 103.1% decrease in net profit to Rs -337 million compared to net profit of Rs 10,783 million during FY22. Revenue of the company fell 30.4% to Rs 4,599 million during FY23.

The current Price to earnings ratio of Panacea Biotech, based on rolling 12 month earnings, stands at -39.6.


Equitymaster requests your view! Post a comment on "Panacea Biotech Gains 12%; BSE HEALTHCARE Index Up 0.6%". Click here!